시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 항응고제 역전제 시장 보고서(2025년)
Anticoagulant Reversal Drugs Global Market Report 2025
상품코드 : 1750907
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,698,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,681,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,665,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

항응고제 역전제 시장 규모는 향후 몇 년간 강력한 성장이 예상됩니다. 질병의 유병률 증가, 계발 캠페인의 확대 등에 기인한다고 생각됩니다. 예측 기간에 예상되는 주요 동향에는 기술의 진보, AI 주도의 신약, 나노의료의 진전, 디지털 헬스 솔루션의 통합, 의약품 공급 관리에 있어서의 블록체인의 이용 등이 포함됩니다.

심혈관질환(CVDs)의 유병률 증가는 항응고제 역전제 시장의 확대를 촉진할 것으로 예측됩니다. 심방세동이나 심부정맥혈전증 등으로 혈액희석제를 복용하고 있는 환자는 정상적인 혈액응고를 회복시키기 위해 신속한 개입을 필요로 하는 생명을 위협하는 출혈에 직면할 가능성이 있기 때문에 CVD 환자는 종종 과잉 출혈 위험을 줄이기 위해 항응고제 역전제을 필요로 합니다. for Health Improvement and Disparities는 2023년 3월까지 회계연도에 영국의 187만 9,000명(3%)이 관상동맥성 심장병(CHD)의 GP 진단을 받았다고 보고했습니다. 차이는 CHD보다 현저하고, 4배의 차이가 인정되어, 하운슬로우에서는 인구 10만명당 396.5명의 입원율을 기록했습니다.

항응고제 역전제 시장의 주요 기업은 치료 효과를 높이고 환자의 안전을 보장하기 위해 기술 혁신, 특히 새로운 역전제 개발에 주력하고 있습니다. 예를 들어, 2022년 3월, 영국의 제약 및 바이오테크놀러지 기업인 아스트라제네카는 생명을 위협하는 출혈시 에 제Xa 인자 억제제(아픽사반, 리버록사반, 에독사반 등)의 작용을 역전시키는 온덱사(안덱사넷 알파)의 승인을 일본에서 취득했습니다. 항-FXa 활성을 빠르고 효과적으로 역전시키는 능력을 입증한 ANNEXA-4 시험에 근거해, 이 목적으로 일본에서 처음으로 승인된 약입니다. 이 승인은 일반적으로 처방되는 이러한 항응고제 역전제에 수반하는 주요한 출혈 리스크에 대처하는 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 태와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Anticoagulant reversal drugs are medications used to counteract the effects of anticoagulants, helping restore normal blood clotting in patients experiencing excessive bleeding. These drugs are typically administered in emergency situations, such as life-threatening hemorrhages or urgent surgeries, to quickly reverse anticoagulation and prevent severe complications.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary anticoagulant reversal drugs include prothrombin complex concentrates, phytonadione (vitamin K), andexanet alfa, idarucizumab, protamine, and others. Prothrombin complex concentrates (PCCs) are blood-derived products containing clotting factors that help manage excessive bleeding. They can be administered via both injectable and oral routes and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. PCCs are used for reversing direct oral anticoagulants (DOACs), warfarin, heparin, low-molecular-weight heparin (LMWH), and other anticoagulant treatments.

The anticoagulant reversal drugs market research report is one of a series of new reports from The Business Research Company that provides anticoagulant reversal drugs market statistics, including anticoagulant reversal drugs industry global market size, regional shares, competitors with a anticoagulant reversal drugs market share, detailed anticoagulant reversal drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anticoagulant reversal drugs industry. This anticoagulant reversal drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anticoagulant reversal drugs market size has grown strongly in recent years. It will grow from$1.52 billion in 2024 to $1.68 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth during the historic period can be attributed to the increase in bleeding disorders, the growing elderly population, expanded healthcare spending, a rise in the prevalence of strokes, and increased investments in the pharmaceutical sector.

The anticoagulant reversal drugs market size is expected to see strong growth in the next few years. It will grow to$2.48 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth during the forecast period can be attributed to the rising demand for antidotes, improvements in healthcare infrastructure, an increasing incidence of thromboembolic disorders, a growing prevalence of cardiovascular diseases, and expanded awareness campaigns. Key trends expected in the forecast period include technological advancements, AI-driven drug discovery, progress in nanomedicine, the integration of digital health solutions, and the use of blockchain in drug supply management.

The growing prevalence of cardiovascular diseases (CVDs) is expected to drive the expansion of the anticoagulant reversal drugs market. CVDs, which encompass heart and blood vessel disorders such as coronary artery disease, stroke, and heart failure, are on the rise, largely due to poor lifestyle choices. Factors such as increased consumption of processed foods, lack of physical activity, and high stress levels contribute to obesity, hypertension, and diabetes. Patients with CVDs often require anticoagulant reversal drugs to mitigate excessive bleeding risks, as individuals on blood thinners for conditions such as atrial fibrillation or deep vein thrombosis may face life-threatening hemorrhages that demand quick intervention to restore normal blood clotting. For example, in December 2024, the Office for Health Improvement and Disparities reported that, in the financial year ending March 2023, 1,879,000 people (3%) in England had a GP diagnosis of coronary heart disease (CHD). Regional variations in heart failure admission rates were more pronounced than for CHD, with a fourfold difference observed, peaking at 396.5 admissions per 100,000 people in Hounslow. This surge in cardiovascular diseases is, therefore, fueling the growth of the anticoagulant reversal drugs market.

Key players in the anticoagulant reversal drugs market are focusing on innovation, particularly the development of new reversal agents, to enhance treatment effectiveness and ensure patient safety. These reversal agents are specialized therapeutics designed to rapidly and selectively counteract the effects of anticoagulants, providing swift and efficient reversal of blood-thinning medications. For example, in March 2022, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, received approval for Ondexxya (andexanet alfa) in Japan to reverse the effects of Factor Xa inhibitors (such as apixaban, rivaroxaban, and edoxaban) during life-threatening bleeds. This was the first approved drug in Japan for this purpose, based on the ANNEXA-4 trial, which demonstrated its ability to rapidly and effectively reverse anti-FXa activity. This approval addresses the major bleeding risks associated with these commonly prescribed anticoagulant drugs.

In February 2025, Novartis AG, a pharmaceutical giant based in Switzerland, acquired Anthos Therapeutics Inc. for $3.1 billion. This acquisition aims to bolster Novartis's cardiovascular portfolio with abelacimab, a next-generation anticoagulant designed to reduce blood clot risks while minimizing bleeding complications. Anthos Therapeutics Inc., a US-based biopharmaceutical company, specializes in developing innovative anticoagulant therapies to address thrombosis-related disorders.

Major players in the anticoagulant reversal drugs market are Pfizer Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, CSL Behring LLC, Daiichi Sankyo Company Limited, Avantor Inc., Daicel Pharma Services GmbH, Octapharma AG, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, AMAG Pharmaceuticals Inc, Glenmark Pharmaceuticals Inc USA, Alexion Pharmaceuticals Inc, Amphastar Pharmaceuticals Inc, Portola Pharmaceuticals Inc, Transo-Pharm USA LLC, and Join Hub Pharma.

North America was the largest region in the anticoagulant reversal drugs market in 2024. The regions covered in anticoagulant reversal drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anticoagulant reversal drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anticoagulant reversal drugs market consists of sales of fresh frozen plasma, tranexamic acid, desmopressin, activated charcoal, and recombinant factor vIIa. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anticoagulant Reversal Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anticoagulant reversal drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for anticoagulant reversal drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anticoagulant reversal drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Anticoagulant Reversal Drugs Market Characteristics

3. Anticoagulant Reversal Drugs Market Trends And Strategies

4. Anticoagulant Reversal Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Anticoagulant Reversal Drugs Growth Analysis And Strategic Analysis Framework

6. Anticoagulant Reversal Drugs Market Segmentation

7. Anticoagulant Reversal Drugs Market Regional And Country Analysis

8. Asia-Pacific Anticoagulant Reversal Drugs Market

9. China Anticoagulant Reversal Drugs Market

10. India Anticoagulant Reversal Drugs Market

11. Japan Anticoagulant Reversal Drugs Market

12. Australia Anticoagulant Reversal Drugs Market

13. Indonesia Anticoagulant Reversal Drugs Market

14. South Korea Anticoagulant Reversal Drugs Market

15. Western Europe Anticoagulant Reversal Drugs Market

16. UK Anticoagulant Reversal Drugs Market

17. Germany Anticoagulant Reversal Drugs Market

18. France Anticoagulant Reversal Drugs Market

19. Italy Anticoagulant Reversal Drugs Market

20. Spain Anticoagulant Reversal Drugs Market

21. Eastern Europe Anticoagulant Reversal Drugs Market

22. Russia Anticoagulant Reversal Drugs Market

23. North America Anticoagulant Reversal Drugs Market

24. USA Anticoagulant Reversal Drugs Market

25. Canada Anticoagulant Reversal Drugs Market

26. South America Anticoagulant Reversal Drugs Market

27. Brazil Anticoagulant Reversal Drugs Market

28. Middle East Anticoagulant Reversal Drugs Market

29. Africa Anticoagulant Reversal Drugs Market

30. Anticoagulant Reversal Drugs Market Competitive Landscape And Company Profiles

31. Anticoagulant Reversal Drugs Market Other Major And Innovative Companies

32. Global Anticoagulant Reversal Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anticoagulant Reversal Drugs Market

34. Recent Developments In The Anticoagulant Reversal Drugs Market

35. Anticoagulant Reversal Drugs Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기